Vivek Subbiah: Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.

In a post by Vivek Subbiah, the Chief Early-Phase Drug Development at Sarah Cannon Research Institute, on LinkedIn, it says:

“At 35 months’ follow-up, the survival benefit of cemiplimab for patients with advanced non-small-cell lung cancer was at least as pronounced as at 1 year, affirming its use as first-line monotherapy for this population. Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.”

For the article click here.
Source: Vivek Subbiah/LinkedIn